Ovarian Neoplasm Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Ovarian Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ovarian CancerOvarian Neoplasms
Merck Sharp & Dohme LLC900 enrolled13 locationsNCT07318558
Recruiting
Not Applicable

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

Quality of LifeDepressive SymptomsOvarian Neoplasm
Baylor College of Medicine120 enrolled3 locationsNCT05752448
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled26 locationsNCT07213791
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled254 locationsNCT07213804
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled154 locationsNCT04389632
Recruiting
Phase 1Phase 2

Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites

AscitesOvarian Neoplasms Malignant
Cancer Institute and Hospital, Chinese Academy of Medical Sciences29 enrolled1 locationNCT07435701
Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Ovarian CarcinomaPrimary Peritoneal CarcinomaLow Grade Ovarian Serous Adenocarcinoma+3 more
M.D. Anderson Cancer Center2,000 enrolled1 locationNCT00488878
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Not Applicable

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

Ovarian CarcinomaOvarian NeoplasmsFemale Reproductive System Adnexal Neoplasm+3 more
Mayo Clinic40 enrolled1 locationNCT07280312
Recruiting

Biomarkers of Resiliency In Childhood Cancer Surgery

SarcomaNeuroblastomaPediatric Cancer+10 more
Mayo Clinic40 enrolled1 locationNCT06674811
Recruiting
Phase 1

A Study of DM002 in Patients With Advanced Solid Tumors

Ovarian NeoplasmsColorectal NeoplasmsEndometrial Neoplasms+2 more
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.160 enrolled5 locationsNCT06751329
Recruiting
Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms
Eli Lilly and Company495 enrolled23 locationsNCT06400472
Recruiting
Not Applicable

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube NeoplasmsOvarian Neoplasm Epithelial+1 more
Swiss GO Trial Group60 enrolled7 locationsNCT06466382
Recruiting
Phase 3

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)

Ovarian Neoplasms
Instituto de Investigacion Sanitaria La Fe200 enrolled1 locationNCT06963268
Recruiting
Not Applicable

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

Ovarian CancerOvarian CarcinomaOvarian Neoplasms+2 more
Gynaecologisch Oncologisch Centrum Zuid90 enrolled1 locationNCT06611072
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Not Applicable

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Ovarian CancerOvarian CarcinomaOvarian Neoplasms
Dana-Farber Cancer Institute112 enrolled1 locationNCT06543537
Recruiting
Phase 2

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Breast NeoplasmsOvarian Neoplasms
GlaxoSmithKline30 enrolled25 locationsNCT04641247